Research Article
Evaluation of a Pilot Medication-Assisted Therapy Program in Kazakhstan: Successes, Challenges, and Opportunities for Scaleup
Table 3
Results of medical chart review for patients on medication-assisted therapy, by treatment site.
| Indicator | Pavlodar | Temirtau | Ust-Kamenogorsk |
| Proportion of patients on MAT with at least one complete clinical review in the last quarter | 0 | 0 | 0 | Proportion of MAT patients screened for hepatitis B | 57% | 85% | 62% | Proportion of MAT patients screened for hepatitis C | 77% | 94% | 59% | Proportion of patients on MAT with at least one psychosocial counseling session during the last month | 21% | 51% | 94%
| Proportion of patients who remained free from nonprescribed opioids1 six months after initiation of MAT | 95% | 68% | 95% | Proportion of patients on MAT remaining in care six months after initiation of MAT | 72% | 55% | 65% | Proportion of patients who remained free from nonprescribed opioids1 twelve months after initiation of MAT | 92% | 41% | 84% | Proportion of patients on MAT remaining in care twelve months after initiation of MAT | 61% | 46% | 61% | Proportion of patients on MAT with at least one sexual- and drug-related risk assessment completed during the last month | 0% | 0% | 0% | Mean daily dose of methadone received by patients enrolled in MAT for three months or longer, mg (standard deviation) | 66 (23,9) | 69 (22,7) | 73 (40,4) |
|
|
1Based on urine toxicology test.
|